| scholarly article | Q13442814 |
| P50 | author | Marcel Leist | Q42136322 |
| P2093 | author name string | A K Larsen | |
| H S Jensen | |||
| J Lotharius | |||
| L Helboe | |||
| M L Pedersen | |||
| M-L Selenica | |||
| P2860 | cites work | Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. | Q47378610 |
| Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes | Q48105061 | ||
| Developmental expression and localization of glycogen synthase kinase-3beta in rat brain | Q48133863 | ||
| Postmortem changes in the phosphorylation state of tau-protein in the rat brain | Q48245898 | ||
| Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding | Q48277664 | ||
| Tau mutations cause frontotemporal dementias | Q48327140 | ||
| Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. | Q48338403 | ||
| Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. | Q48600800 | ||
| Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. | Q48622377 | ||
| Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons | Q48658321 | ||
| Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain | Q48822557 | ||
| cDNA cloning and properties of glycogen synthase kinase-3. | Q48829897 | ||
| Distribution of tau protein kinase I/glycogen synthase kinase-3beta, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain. | Q52170466 | ||
| Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. | Q52170853 | ||
| Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. | Q52206922 | ||
| Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. | Q52212514 | ||
| Extracellular neurofibrillary tangles associated with degenerating neurites and neuropil threads in Alzheimer-type dementia. | Q53182764 | ||
| Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 | Q60603655 | ||
| Involvement of tau protein kinase I in paired helical filament-like phosphorylation of the juvenile tau in rat brain | Q72632465 | ||
| A protein factor essential for microtubule assembly | Q22010837 | ||
| Tau pathology in Alzheimer disease and other tauopathies | Q22252520 | ||
| A molecular mechanism for the effect of lithium on development | Q24629067 | ||
| Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 | Q27641873 | ||
| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B | Q27860731 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | Q28115206 | ||
| Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation | Q28140761 | ||
| GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides | Q28205921 | ||
| Glycogen synthase kinase-3: functions in oncogenesis and development | Q28212979 | ||
| Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease | Q28242505 | ||
| New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry | Q28290064 | ||
| Microtubule bundling by tau proteins in vivo: analysis of functional domains | Q28565528 | ||
| Molecular cloning and expression of glycogen synthase kinase-3/factor A | Q28569645 | ||
| A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) | Q28640016 | ||
| Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease | Q28910345 | ||
| Tau suppression in a neurodegenerative mouse model improves memory function | Q29615831 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells | Q29618245 | ||
| Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. | Q30613304 | ||
| Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription | Q31462537 | ||
| Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo | Q33771431 | ||
| PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus | Q33938971 | ||
| Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo | Q34179931 | ||
| Molecular targets of lithium action | Q34192797 | ||
| The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. | Q34327099 | ||
| Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes | Q35216433 | ||
| Glycogen synthase kinase-3 as drug target: from wallflower to center of attention | Q35619001 | ||
| Pharmacological inhibitors of glycogen synthase kinase 3. | Q35960333 | ||
| Functional interactions of tau and their relevance for Alzheimer's disease. | Q36173165 | ||
| Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies | Q36174549 | ||
| Glycogen synthase kinase-3--an overview of an over-achieving protein kinase | Q36651778 | ||
| Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease | Q36651782 | ||
| Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders | Q36651786 | ||
| The role of tau phosphorylation in the pathogenesis of Alzheimer's disease | Q36683211 | ||
| Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade | Q37416273 | ||
| Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice | Q38585196 | ||
| A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation | Q40190612 | ||
| Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation | Q40243412 | ||
| Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). | Q40372287 | ||
| Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. | Q40401086 | ||
| Tau domains, phosphorylation, and interactions with microtubules. | Q40416733 | ||
| Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line | Q40714967 | ||
| The tau proteins in neuronal growth and development | Q41477226 | ||
| Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state | Q41525580 | ||
| Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein | Q42795195 | ||
| Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? | Q43507724 | ||
| Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death | Q43560460 | ||
| Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse | Q43664665 | ||
| First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease | Q43907791 | ||
| Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium | Q44264546 | ||
| GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila | Q44782542 | ||
| Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. | Q46492112 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 959-979 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation | |
| P478 | volume | 152 |
| Q41905676 | 4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin |
| Q37448714 | 7,8-Dihydroxyflavone Ameliorates Cognitive Impairment by Inhibiting Expression of Tau Pathology in ApoE-Knockout Mice. |
| Q37341837 | A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. |
| Q42604157 | A mitotic role for GSK-3beta kinase in Drosophila. |
| Q35321539 | Advances in tau-based drug discovery. |
| Q37606284 | Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies |
| Q37084011 | Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy |
| Q37733587 | An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders |
| Q48330860 | Caloric restriction mimetic 2-deoxyglucose maintains cytoarchitecture and reduces tau phosphorylation in primary culture of mouse hippocampal pyramidal neurons |
| Q37528700 | Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells. |
| Q28388774 | Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities |
| Q37048487 | Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models |
| Q34328541 | Dimethyl sulfoxide induces both direct and indirect tau hyperphosphorylation. |
| Q24322974 | Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling |
| Q61799504 | Dissecting the roles of β-arrestin2 and GSK-3 signaling in 5-HT1BR-mediated perseverative behavior and prepulse inhibition deficits in mice |
| Q43054770 | Effect of GSK-3 activity, enzymatic inhibition and gene silencing by RNAi on tick oviposition and egg hatching. |
| Q53444102 | Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. |
| Q42641582 | From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data |
| Q35086876 | Frontiers in Alzheimer's disease therapeutics |
| Q21129334 | GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS |
| Q35001040 | GSK-3 in Neurodegenerative Diseases. |
| Q33747040 | Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism |
| Q30474415 | Glycogen synthase kinase-3 in the etiology and treatment of mood disorders |
| Q54622020 | Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. |
| Q38126701 | Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments |
| Q38753758 | In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities |
| Q42554535 | Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV |
| Q47117649 | Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates Aβ Oligomer-Induced Cognitive Impairments in Mice |
| Q53437323 | Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis. |
| Q51643185 | Indirubin-3-Oxime Prevents H2O2-Induced Neuronal Apoptosis via Concurrently Inhibiting GSK3β and the ERK Pathway. |
| Q28485938 | Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice |
| Q30532196 | Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway |
| Q91983085 | Modified recipe to inhibit fruiting body formation for living fungal biomaterial manufacture |
| Q54980306 | Modulation of GSK-3β/β-Catenin Signaling Contributes to Learning and Memory Impairment in a Rat Model of Depression. |
| Q36617889 | Natural products as a rich source of tau-targeting drugs for Alzheimer's disease |
| Q34629320 | Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin |
| Q24620383 | Novel therapeutics for Alzheimer's disease: an update |
| Q93332761 | Overview and Current Status of Alzheimer's Disease in Bangladesh |
| Q39571308 | Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. |
| Q41470342 | Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins |
| Q36128825 | Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models |
| Q40079572 | Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice |
| Q33671660 | Targeting protein kinases in central nervous system disorders |
| Q43243781 | Tau hyperphosphorylation and axonal damage induced by N,N-diethyldithiocarbamate (DEDTC) treatment along late postnatal development is followed by a rescue during adulthood |
| Q28256824 | The acetyltransferase Tip60 is a critical regulator of the differentiation-dependent amplification of human papillomaviruses |
| Q48957769 | The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons |
| Q37098587 | The role of GSK-3 in synaptic plasticity. |
| Q34409349 | Therapy for Alzheimer's Disease: How Effective are Current Treatments? |
| Q54217663 | Transplantation of Human Menstrual Blood-Derived Mesenchymal Stem Cells Alleviates Alzheimer's Disease-Like Pathology in APP/PS1 Transgenic Mice. |
Search more.